AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Epidemiological Data on Mast Cell Pathologies in France

Recruitingn/aAges any - anyAllImagine Institute
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Mast cell disorders constitute a heterogeneous group of diseases, including : * mastocytosis, i.e. cutaneous, indolent and severe forms of the disease, such as aggressive mastocytosis and mast cell leukemia) ; * mast cell-associated diseases such as mast cell activation syndrome (idiopathic, secondary or clonal), affecting both children and adults. No epidemiological data are currently available in France. In France, medical care of mast cell disorders is mainly provided by a rare disease network (CEREMAST), whose CRMR is located at the Necker Enfants Malades hospital in Paris. A total of 20 centers are located throughout France. Our aim is to use this network to study patients suffering from these diseases. The overall aim of the study is to improve the understanding, diagnosis, prognosis, recognition and management of patients with mastocytosis.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Children from birth and adults of any age 2. With one of the following mast cell diseases: * Mastocytoses (cutaneous, systemic and sarcomas) Defined according to the WHO 2016 classification * Mast cell activation syndromes (idiopathic, secondary and clonal) * Other mast cell activation disorders (MCAD-NOS), Defined according to the Vienna classification * Pre-mastocytosis or MMC (1 to 2 criteria according to WHO 2016 classification). 3. Managed in France in a rare disease reference, constitutive or competence center (CEREMAST) with DGOS labelization. Exclusion Criteria: 1\. Opposition of the patient or his/her parents to participation in the study.
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

21 sites
CHU AMIENS site sud
Amiens, France
Chu Angers
Angers, France
Chu - Besancon
Besanรงon, France
Chu - Caen
Caen, France
Chu - Clermont Ferrand
Clermont-Ferrand, France
CHU Grenoble
Grenoble, France
Chru Lille
Lille, France
Chu - Limoges
Limoges, France

โ€ฆand 13 more on ClinicalTrials.gov.

๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy